MétaCan
Menu
Back to cohort
Record W3026001080 · doi:10.1111/apt.15784

Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy

2020· article· en· W3026001080 on OpenAlexfundno aff
Uri Kopylov, Jurij Hanžel, Claire Liefferinckx, Davide De Marco, Nicola Imperatore, Nikolas Plevris, Iria Bastón‐Rey, Richard Harris, Marie Truyens, Viktor Domislović, Stephan R. Vavricka, Vince Biemans, Sally Myers, Shaji Sebastian, Shomron Ben‐Horin, Yago González Lama, Cyrielle Gilletta, Bar‐Gil Shitrit Ariella, Zuzana Zelinková, Roni Weisshof, Darragh Storan, Eran Zittan, Klaudia Farkas, Tamás Molnár, Denis Franchimont, Anneline Cremer, Waqqas Afif, Fabiana Castiglione, Charlie W. Lees, Manuel Barreiro‐de Acosta, Triana Lobatón, Glen Doherty, Željko Krznarić, Marieke Pierik, Frank Hoentjen, David Drobne

Bibliographic record

VenueAlimentary Pharmacology & Therapeutics · 2020
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicInflammatory Bowel Disease
Canadian institutionsnot available
FundersSzegedi TudományegyetemRadboud Universitair Medisch CentrumUniversiteit GentUniversitair Ziekenhuis GentTel Aviv UniversityUniversiteit MaastrichtTechnion-Israel Institute of TechnologyRadboud UniversiteitMcGill UniversityMcGill University Health CentreHebrew University of JerusalemUniversity College DublinUniverza v LjubljaniMaastricht Universitair Medisch CentrumUniversity Hospital Southampton NHS Foundation Trust
KeywordsMedicineUstekinumabCrohn's diseaseRetrospective cohort studyMaintenance therapyInternal medicineSurgeryDiseaseChemotherapyAdalimumab

Abstract

fetched live from OpenAlex

BACKGROUND: Ustekinumab is effective in Crohn's disease. However, a substantial proportion of patients will not respond or lose response to ustekinumab. The current evidence to support the effectiveness of dose-optimisation for ustekinumab nonresponse is limited. AIM: To assess the effectiveness of dose escalation of ustekinumab. METHODS: This was a multicentre retrospective cohort study. We included active Crohn's disease patients who received a standard-dose intravenous induction and at least one subcutaneous ustekinumab 90 mg dose. All enrolled patients received dose escalation by either shortening the interval between the doses to every 4 or 6 weeks, intravenous reinduction or a combination of strategies. The primary outcome of the study was clinical response at week 16 after dose escalation. RESULTS: A total of 142 patients (22 centres/14 countries) were included. The patients were dose-escalated after a median treatment duration of 30 weeks. At week 16 from escalation, 73/142 (51.4%) responded to treatment, including 55/142 (38.7%) in clinical remission. Corticosteroid-free remission was achieved in 6/34 (17.6%) patients on corticosteroids at the time of escalation; 118/142 (83%) continued treatment beyond week 16. Follow-up data beyond week 16 were available for 74/118 (62.7%) patients. On the last follow-up, 51/98 (52%) patients with available data responded to treatment, including 41/98 (42%) in clinical remission. CONCLUSIONS: Intensification of ustekinumab maintenance dosage was effective in over 50% of the patients. This strategy should be considered in patients who are nonresponsive to every 8 weeks ustekinumab maintenance dosing.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.747
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.010
GPT teacher head0.265
Teacher spread0.255 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations80
Published2020
Admission routes1
Has abstractyes

Explore more

Same venueAlimentary Pharmacology & TherapeuticsSame topicInflammatory Bowel DiseaseFrench-language works237,207